ReviewMetabolic brain disease2026
Lactate as a metabolic-epigenetic hub in neurological disorders.
Review in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Lactate, once considered merely a metabolic waste product of glycolysis, has emerged as a pivotal signaling molecule that bridges cellular metabolism and epigenetic regulation in the central nervous system. The discovery of protein lactylation in 2019 revealed a novel post-translational modification that directly linked lactate accumulation to changes in gene expression, fundamentally reshaping our understanding of how metabolic states influenced neural function and dysfunction. This comprehensive review synthesizes recent advances in lactate biology, encompassing the expanding enzymatic landscape of lactylation-including newly identified writers, erasers, and readers-and their roles in neurodegenerative diseases. We critically re-examine metabolic coupling models beyond the classical astrocyte-neuron lactate shuttle (ANLS), incorporating neuronal glycolytic capacity, oligodendrocyte-specific relay mechanisms, and cell type-specific monocarboxylate transporter (MCT) expression patterns. Furthermore, we explore the concentration-dependent duality of lactate effects through G protein-coupled receptor 81 (GPR81)/hydroxycarboxylic acid receptor 1 (HCAR1) signaling, the functional significance of non-histone lactylation in neural cells, and the interplay between lactylation and mitochondrial quality control, ferroptosis, and adult hippocampal neurogenesis. Finally, we discuss emerging therapeutic strategies targeting lactate metabolism and lactylation modifications -ranging from lactate dehydrogenase (LDH) inhibitors and MCT modulators to exercise-induced neuroprotection-and identify critical challenges for clinical translation. By integrating these cutting-edge findings, we provide an updated theoretical framework that positions lactate as a central node connecting metabolic reprogramming with epigenetic dysregulation in neurodegeneration.
Indexed as
Identifiers
42720802What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.